Shyam Morjaria
Introduction
Shyam Morjaria was the superintendent pharmacist and a director of UK Meds Direct Limited, one of the UK’s largest online pharmacies, until the General Pharmaceutical Council struck him from the register over systemic safety failures in the company’s prescribing and dispensing. During his tenure as superintendent pharmacist the company issued nearly 379,000 prescriptions for high-risk medicines, controlled drugs and addiction-forming treatments; the GPhC’s fitness-to-practise committee found the business operated a “transactional” model prioritising speed, volume and commercial profit over patient-centred care, and that Morjaria — who oversaw it — failed to implement the safety governance that might have contained the harm. Vulnerable patients with histories of mental-health issues, addiction and self-harm obtained large quantities of high-risk medicines without GP knowledge, with severe overdoses and fatalities among the outcomes.
Background Information
Morjaria joined UK Meds in September 2018 as responsible pharmacist and was appointed superintendent pharmacist the following month; from May 2020 he was also a director of the company. He remained in the superintendent role until 6 September 2021 — the day before UK Meds voluntarily removed itself from the GPhC register after failing successive GPhC inspections and having several conditions orders imposed. The scale at issue was extraordinary for a single online operator: as superintendent he oversaw the prescribing of around 378,885 high-risk medicines, including opioids, amitriptyline and propranolol, and as responsible pharmacist supervised the dispensing of around 43,000 high-risk medicines. GPhC inspectors visiting between 2019 and 2020 found the required safety governance, audit structures and risk assessments were not in place — and rather than rectifying the deficiencies, the company ultimately left the register. The tip-off trail ran through international channels: in December 2022 a GPhC inspector visited after the MHRA received a tip-off from the United Nations that packages despatched from the premises had been intercepted by US Customs.
The Controversy or Incident That Led to Their Cancellation
Adjudicated vs. alleged. The findings against Morjaria were made by the GPhC’s Fitness to Practise Committee after a remote hearing that began on 29 June and concluded on 31 July. They are regulatory findings, not criminal convictions; no criminal proceedings against Morjaria are reported in the coverage. The committee’s determination and the statistics above are from the GPhC’s published position.
The committee heard evidence involving vulnerable patients — people with histories of mental-health issues, addiction and self-harm — who were able to obtain large quantities of high-risk medicines without GP knowledge or safety-netting, leading to severe overdoses and fatalities. It was alleged there was informed consent from patients on only 8,136 occasions across almost half a million occasions of high-risk medication being prescribed. The panel reviewed the inspection history: Morjaria failed to implement required safety governance, audit structures or risk assessments between 2019 and 2020, and the deficiencies were never rectified — the company instead deregistered. Morjaria did not attend the hearing but submitted written reflections expressing regret for patient harm and stating he no longer intends to practise pharmacy. The committee determined he demonstrated limited insight, failed to exercise professional leadership, and showed an attitudinal failure by placing commercial objectives above patient safety, and that his actions and oversights were “fundamentally incompatible” with continued registration. An immediate interim suspension order was imposed pending the removal coming into force.
Public Reaction and Consequences
The case was covered across the pharmacy trade press under headlines like “Patients suffered harm,” and it landed in a sector already primed by the UK Meds file: previous GPhC rulings against the company’s staff include an experienced pharmacist struck off and two suspended over unsafe online dispensing, and a pharmacist struck off for issuing prescriptions in under a minute. The committee’s conclusion that “the only outcome” protecting the public and the profession’s reputation was removal placed Morjaria at the top of the sanction range for the online-pharmacy misconduct wave. The UN/MHRA/US Customs angle — packages intercepted across the Atlantic — gave the enforcement story international reach. An immediate interim suspension means he could not practise between the hearing and the removal taking effect.
Current Status
Morjaria has been removed from the GPhC register, with an immediate interim suspension order in force pending the removal order’s final coming into force. He told the committee he no longer intends to practise pharmacy. UK Meds Direct Limited remains off the register following its September 2021 voluntary removal. The committee’s findings about the prescribing model — nearly 379,000 high-risk prescriptions, informed consent on roughly 2% of occasions, overdoses and fatalities — stand as the public record of the company’s operation under his leadership.
Impact on Their Career/Life
A career that reached the top of UK community pharmacy governance — superintendent pharmacist of a major online operator, company director — ended with removal from the register and a findings record citing failed leadership at scale. The case is now the sector’s reference point for superintendent accountability: the GPhC treated the failures not as a company problem but as a pharmacist’s personal unfitness, on the theory that the superintendent role exists precisely to prevent what happened. For the online-pharmacy model, the UK Meds file — conditions, failed inspections, deregistration, then a wave of staff erasures topped by Morjaria — documents how growth-first prescribing ran into the regulator a step at a time, with patients’ overdoses and deaths as the background cost. His written regret and stated intention never to practise again were noted, but the committee’s “limited insight” finding explains why regret did not translate into a lesser sanction.